Stempeutics to introduce new stem cell products by 2014
According to the company, the products are likely to complete their phase III trials by early 2014, facilitating the launch, news.in.msn.com reports. The Phase II trials are expected
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The approval has been confirmed for the UK, Belgium, Finland, Ireland, Luxemburg, Netherlands and Sweden. Octapharma’s manufacturing process for OctaplasLG, which is a solvent/detergent treated, prion-reduced, plasma product